Why TG Therapeutics, Inc. (TGTX) stock moved
TG Therapeutics, Inc. (TGTX) shares fell 0.0% to $53.95 as of July 22, 2026, a slight decline from the prior close of $53.96. BestStocks flagged the session as a major change for TGTX. No single company-specific catalyst was confirmed during the move window. Below, we break down what changed for TGTX, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
TGTX fell 0.0% to $53.95
TGTX moved -2.62% from $56.41 to $54.93 on 2026-07-16. We checked news, earnings, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was near its 5-day average, suggesting the move was not driven by unusual trading activity. Watch for earnings announcements, clinical trial updates, or analyst commentary that could explain the recent price action.
What it means for TG Therapeutics, Inc. investors
For TG Therapeutics, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: TG Therapeutics, Inc. (TGTX) moved +2.77% from $54.89 to $56.41 on 2026-07-15; TG Therapeutics, Inc. (TGTX) moved +3.20% from $57.23 to $59.06 on 2026-07-09, reaching a new 30-day high. Weighing against that: Negative session, down 0.0%; TGTX moved -2.62% from $56.41 to $54.93 on 2026-07-16. Wall Street's consensus price target sits at $76.50, implying +41.8% upside from $53.95. BestStocks rates the overall signal quality weak (0/100). With earnings roughly 12 days out, the next report is the most likely near-term test of the move.
TGTX price reaction
TGTX last traded at $53.95, down $0.01 (-0.02%) from the previous close of $53.96. The session traded on 0.6× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $53.31 and $59.06, and it currently sits about 11% of the way up that band.
Bullish and bearish analyst opinions on TG Therapeutics, Inc. (TGTX)
The consensus analyst price target on TG Therapeutics, Inc. (TGTX) is $76.50, 41.8% above the recent $53.95. Over the past 90 days analysts logged 0 upgrades, 5 maintains, and 0 downgrades. Here is how the bullish and bearish cases on TGTX line up.
The bullish case
- Wall Street's consensus price target of $76.50 implies +41.8% upside from $53.95.
- The Street's most bullish target is $83.00 (+53.8%).
- TG Therapeutics, Inc. (TGTX) moved +2.77% from $54.89 to $56.41 on 2026-07-15.
- Positive price momentum.
The bearish case
- Negative session, down 0.0%.
- TGTX moved -2.62% from $56.41 to $54.93 on 2026-07-16.
- TG Therapeutics, Inc. (TGTX) moved -3.69% from $57.12 to $55.01 on 2026-07-13.
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 22, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for TGTX
Frequently asked questions about TGTX
Why did TG Therapeutics, Inc. (TGTX) stock move?
TGTX fell 0.0% to $53.95. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did TGTX stock fall?
TGTX lost 0.02% ($0.01) versus the prior close of $53.96, last trading at $53.95 on 0.6× average volume.
When is TG Therapeutics, Inc.'s next earnings date?
TGTX's next earnings report is estimated for 2026-08-03 — about 12 days away.
What is the analyst price target for TGTX?
The consensus analyst price target for TGTX is $76.50, about 41.8% above the current $53.95. Over the past 90 days, analysts recorded 0 upgrades, 5 maintains, and 0 downgrades.
How BestStocks tracks TGTX
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared TGTX-specific materiality thresholds, triggering an evidence check. It draws on 11 tracked change events for TGTX, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 22, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.